簡易神経伝導速度測定機器（DPNチェックHDN-1000，以下HDN-1000）を用いて，糖尿病患者の血糖コントロールが短期間に神経機能に与える影響について検討した。糖尿病患者30人を対象とし，HDN-1000を用いて入院時と退院時に腓腹神経の感覚神経伝導速度（SNCV）および活動電位振幅（SNAP）を測定し，比較検討した。腓腹神経SNCVは入院期間中（平均16.5日間）に明らかな変化はみられなかったが，SNAPは左側9.3±5.8μVから12.7±7.7μV（p＜0.01），右側9.0±5.0から10.7±5.7μV（p＜0.05）と有意に改善した。HDN-1000は繰り返しの末梢神経機能測定に有用であり，本検討により短期的な血糖コントロールによっても神経電位振幅が改善すること，また，伝導速度よりも電位振幅の改善の方が早期に認められることが示唆された。

   This study determined whether short-term glycemic control improved neurological function in diabetes patients using a bedside Point-of-Care Nerve Conduction Device (HDN-1000), which was newly approved to evaluate sensory nerve conduction velocity (SNCV) and sensory nerve action potential (SNAP) of the sural nerve. Thirty short-term hospitalization diabetes patients (four type 1 and 26 type 2 diabetes) were enrolled in this study and retrospectively analyzed. Average fasting blood glucose levels improved from 203.5 mg/dL to 134.5 mg/dL during hospitalization (average 16.5 days). Interestingly, bilateral SNAP significantly improved (left: 9.3 ± 5.8 to 12.7 ± 7.7 μV (p＜0.01), right: 9.0 ± 5.0 to 10.7 ± 5.7 μV (p＜0.05)), although there were no significant bilateral SNCV differences. Results showed that SNAP was effectively and significantly improved by short-term glycemic control, suggesting that the device of HDN-1000 was convenient for repeated peripheral nerve function measurements, as well as reduced invasiveness and stress to the patient.